lansoprazole has been researched along with Hematochezia in 29 studies
Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.
Hematochezia: The passage of bright red blood from the rectum. The blood may or may not be mixed with formed stool in the form of blood, blood clots, bloody stool or diarrhea.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To describe a case of thrombocytopenia associated with the administration of lansoprazole." | 7.71 | Lansoprazole-induced thrombocytopenia. ( Anderson, CG; Zlabek, JA, 2002) |
| "To assess the non-inferiority of vonoprazan to lansoprazole for secondary prevention of non-steroidal anti-inflammatory drug (NSAID)-induced peptic ulcer (PU) and the safety of vonoprazan during extended use." | 5.27 | Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study. ( Ashida, K; Funao, N; Kawai, T; Mizokami, Y; Nishimura, A; Oda, K; Soen, S; Sugano, K, 2018) |
| "Compare efficacy and safety of vonoprazan and lansoprazole for secondary prevention of low-dose aspirin (LDA)-associated peptic ulcers in a 24-week study and long-term extension therapy in separate study." | 5.27 | Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study. ( Ashida, K; Funao, N; Kawai, T; Matsumoto, Y; Mizokami, Y; Nishimura, A; Oda, K; Sugano, K, 2018) |
| ", omeprazole, misoprostol, and high-dose famotidine) in the prevention of NSAID-induced gastroduodenal ulcers will also be effective in this setting." | 3.71 | Current approaches to reducing gastrointestinal toxicity of low-dose aspirin. ( Lanas, AI, 2001) |
| "To describe a case of thrombocytopenia associated with the administration of lansoprazole." | 3.71 | Lansoprazole-induced thrombocytopenia. ( Anderson, CG; Zlabek, JA, 2002) |
| "His only medical history was mild Alzheimer's disease diagnosed 6 months prior." | 2.52 | Upper gastrointestinal bleed associated with cholinesterase inhibitor use. ( Kok, KS; Loke, Y; Southgate, J, 2015) |
| "lansoprazole was 0." | 1.91 | Cost-Effectiveness of Vonoprazan Compared With Proton Pump Inhibitors in Patients Taking Low-Dose Aspirin for Secondary Prevention of Cardiovascular Events in Japan. ( Deguchi, H; Fernandez, J; Igarashi, A; Ishii, M; Kawai, T; Suzuki, M; Tsujita, K, 2023) |
| "Omeprazole treatment did not result in mucosal injury or inflammation; however, there were marked shifts in numbers and types of enteric bacteria, including a significant reduction (∼80%) of jejunal Actinobacteria and Bifidobacteria spp." | 1.37 | Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. ( Bercik, P; Bolla, M; Collins, SM; de Palma, G; Denou, E; Jury, J; McKnight, W; Ongini, E; Syer, S; Verdu, E; Vong, L; Wallace, JL, 2011) |
| "(1) The majority of trauma admissions are at high risk for developing gastrointestinal haemorrhage." | 1.36 | Gastroprotection in trauma patients receiving non-steroidal anti-inflammatory drugs. ( Chan, JK; Graham, A; Phoenix, G; Sharma, S; Sleat, G, 2010) |
| "Lansoprazole was more potent than omeprazole, famotidine and ranitidine in inhibiting gastric mucosal lesions and hemorrhagic shock- or stress-induced bleeding." | 1.29 | [Effects of intravenous lansoprazole on acute gastric mucosal lesions and acid secretion]. ( Asano, S; Inada, I; Inatomi, N; Murakami, I; Satoh, H, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (17.24) | 18.2507 |
| 2000's | 8 (27.59) | 29.6817 |
| 2010's | 13 (44.83) | 24.3611 |
| 2020's | 3 (10.34) | 2.80 |
| Authors | Studies |
|---|---|
| Ishii, M | 1 |
| Kawai, T | 3 |
| Tsujita, K | 1 |
| Igarashi, A | 1 |
| Suzuki, M | 1 |
| Deguchi, H | 1 |
| Fernandez, J | 1 |
| Páramo-Zunzunegui, J | 1 |
| Ortega-Fernandez, I | 1 |
| Benito-Barbero, S | 1 |
| Rubio-López, L | 1 |
| Parton, JR | 1 |
| Ritchie, J | 1 |
| Mizokami, Y | 2 |
| Oda, K | 2 |
| Funao, N | 2 |
| Nishimura, A | 2 |
| Soen, S | 1 |
| Ashida, K | 2 |
| Sugano, K | 2 |
| Matsumoto, Y | 1 |
| Ishido, K | 1 |
| Tanabe, S | 1 |
| Azuma, M | 1 |
| Katada, C | 1 |
| Wada, T | 1 |
| Yano, T | 1 |
| Koizumi, W | 1 |
| Oe, S | 1 |
| Watanabe, T | 1 |
| Kume, K | 1 |
| Shibata, M | 1 |
| Hiura, M | 1 |
| Yoshikawa, I | 1 |
| Harada, M | 1 |
| Bennett, C | 1 |
| Klingenberg, SL | 2 |
| Langholz, E | 2 |
| Gluud, LL | 2 |
| Kok, KS | 1 |
| Loke, Y | 1 |
| Southgate, J | 1 |
| Lin, PY | 1 |
| Tang, JH | 1 |
| Chang, CC | 1 |
| Chatterjee, S | 1 |
| Couto, G | 1 |
| Bispo, M | 1 |
| Barreiro, P | 1 |
| Monteiro, L | 1 |
| Matos, L | 1 |
| Bretagne, JF | 1 |
| Chan, JK | 1 |
| Sleat, G | 1 |
| Sharma, S | 1 |
| Phoenix, G | 1 |
| Graham, A | 1 |
| Brophy, GM | 1 |
| Brackbill, ML | 1 |
| Bidwell, KL | 1 |
| Brophy, DF | 1 |
| Wallace, JL | 1 |
| Syer, S | 1 |
| Denou, E | 1 |
| de Palma, G | 1 |
| Vong, L | 1 |
| McKnight, W | 1 |
| Jury, J | 1 |
| Bolla, M | 1 |
| Bercik, P | 1 |
| Collins, SM | 1 |
| Verdu, E | 1 |
| Ongini, E | 1 |
| Imaeda, H | 1 |
| Hosoe, N | 1 |
| Suzuki, H | 1 |
| Saito, Y | 1 |
| Ida, Y | 1 |
| Nakamura, R | 1 |
| Iwao, Y | 1 |
| Ogata, H | 1 |
| Hibi, T | 1 |
| Lim, YJ | 1 |
| Phan, TM | 1 |
| Dial, EJ | 1 |
| Graham, DY | 1 |
| Lichtenberger, LM | 1 |
| Agustí-Escasany, A | 1 |
| Vallano-Ferraz, A | 1 |
| Inatomi, N | 3 |
| Nitta, K | 1 |
| Sakurai, Y | 1 |
| Aoki, T | 1 |
| Michel, P | 1 |
| Duhamel, C | 1 |
| Bazin, B | 1 |
| Raoul, JL | 1 |
| Person, B | 1 |
| Bigard, MA | 1 |
| Legoux, JL | 1 |
| Sallerin, V | 1 |
| Colin, R | 1 |
| Murakami, I | 2 |
| Asano, S | 2 |
| Inada, I | 1 |
| Satoh, H | 2 |
| Yukishige, K | 1 |
| Nagaya, H | 1 |
| Howden, CW | 1 |
| Lanas, AI | 1 |
| Hawkey, GM | 1 |
| Cole, AT | 1 |
| McIntyre, AS | 1 |
| Long, RG | 1 |
| Hawkey, CJ | 1 |
| Zlabek, JA | 1 |
| Anderson, CG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 3, Multicenter, Randomized, Double-blind, AG-1749-controlled, Parallel-group, Comparison Study to Evaluate the Efficacy and Safety of TAK-438 (10 mg or 20 mg, Orally, Once Daily) for the Prevention of Recurrent Gastric or Duodenal Ulcers During Lo[NCT01452750] | Phase 3 | 642 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| A Phase 3, Multicenter, Single-blind, AG-1749-controlled, Parallel-group, Long-term Extension Study to Evaluate the Safety and Efficacy of TAK-438 (10 mg or 20 mg, Orally, Once Daily) for the Prevention of Recurrent Gastric or Duodenal Ulcers During Long-[NCT01456260] | Phase 3 | 406 participants (Actual) | Interventional | 2011-09-30 | Completed | ||
| A Phase 3, Multicenter, Randomized, Double-blind, AG-1749-controlled, Parallel-group, Comparison Study to Evaluate the Efficacy and Safety of TAK-438 (10 mg or 20 mg, Orally, Once Daily) for the Prevention of Recurrent Gastric or Duodenal Ulcers During Lo[NCT01452763] | Phase 3 | 621 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| A Phase 3, Multicenter, Single-blind, AG-1749-controlled, Parallel-group, Long-term Extension Study to Evaluate the Safety and Efficacy of TAK-438 (10 mg or 20 mg, Orally, Once Daily) for the Prevention of Recurrent Gastric or Duodenal Ulcers During Long-[NCT01456247] | Phase 3 | 439 participants (Actual) | Interventional | 2012-03-31 | Completed | ||
| Pilot RCT: Use of Tranexamic Acid (TXA) in Post Mastectomy Patients for Seroma and Hematoma Prevention[NCT03738527] | Phase 4 | 100 participants (Anticipated) | Interventional | 2019-10-07 | Recruiting | ||
| The Role of Tranexamic Acid for the Treatment of Gastrointestinal Bleeding: A Randomized Double-blind Controlled Trial[NCT03540368] | 336 participants (Anticipated) | Interventional | 2018-07-04 | Suspended (stopped due to increased number of patients death) | |||
| Tranexamic Acid to Prevent Bleeding After Endoscopic Resection of Large Colorectal Polyps: A Pilot Project[NCT04559880] | Phase 4 | 25 participants (Actual) | Interventional | 2020-09-10 | Active, not recruiting | ||
| Local Administration of Tranexamic Acid in Upper Gastrointestinal Hemorrhage: A Double-Blind, Randomized, Placebo-Controlled Trial[NCT02903017] | Phase 4 | 114 participants (Actual) | Interventional | 2016-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for lansoprazole and Hematochezia
| Article | Year |
|---|---|
Tranexamic acid for upper gastrointestinal bleeding.
Topics: Administration, Oral; Aluminum Hydroxide; Anti-Ulcer Agents; Antifibrinolytic Agents; Cimetidine; Dr | 2014 |
Tranexamic acid for upper gastrointestinal bleeding.
Topics: Administration, Oral; Aluminum Hydroxide; Anti-Ulcer Agents; Antifibrinolytic Agents; Cimetidine; Dr | 2014 |
Tranexamic acid for upper gastrointestinal bleeding.
Topics: Administration, Oral; Aluminum Hydroxide; Anti-Ulcer Agents; Antifibrinolytic Agents; Cimetidine; Dr | 2014 |
Tranexamic acid for upper gastrointestinal bleeding.
Topics: Administration, Oral; Aluminum Hydroxide; Anti-Ulcer Agents; Antifibrinolytic Agents; Cimetidine; Dr | 2014 |
Tranexamic acid for upper gastrointestinal bleeding.
Topics: Administration, Oral; Aluminum Hydroxide; Anti-Ulcer Agents; Antifibrinolytic Agents; Cimetidine; Dr | 2014 |
Tranexamic acid for upper gastrointestinal bleeding.
Topics: Administration, Oral; Aluminum Hydroxide; Anti-Ulcer Agents; Antifibrinolytic Agents; Cimetidine; Dr | 2014 |
Tranexamic acid for upper gastrointestinal bleeding.
Topics: Administration, Oral; Aluminum Hydroxide; Anti-Ulcer Agents; Antifibrinolytic Agents; Cimetidine; Dr | 2014 |
Tranexamic acid for upper gastrointestinal bleeding.
Topics: Administration, Oral; Aluminum Hydroxide; Anti-Ulcer Agents; Antifibrinolytic Agents; Cimetidine; Dr | 2014 |
Tranexamic acid for upper gastrointestinal bleeding.
Topics: Administration, Oral; Aluminum Hydroxide; Anti-Ulcer Agents; Antifibrinolytic Agents; Cimetidine; Dr | 2014 |
Upper gastrointestinal bleed associated with cholinesterase inhibitor use.
Topics: Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Duodenal Ulcer; Endoscop | 2015 |
[Prevention of GI bleeding due to antiplatelet agents: a labyrinth!].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aspirin; Clopidogrel; Drug Interactions; Drug Therapy, Comb | 2009 |
Tranexamic acid for upper gastrointestinal bleeding.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Aluminum Hydroxide; Anti-Ulcer Agents | 2012 |
[Pharmacological and clinical profile of lansoprazole (Takepron IV injection 30 mg)].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Gastric Acid; Gastric Mucosa; G | 2008 |
Use of proton-pump inhibitors in complicated ulcer disease and upper gastrointestinal tract bleeding.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroi | 1999 |
8 trials available for lansoprazole and Hematochezia
| Article | Year |
|---|---|
Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Double-Blind Method; Equivalence T | 2018 |
Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Double-Blind Method; Equivalence T | 2018 |
Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Double-Blind Method; Equivalence T | 2018 |
Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Double-Blind Method; Equivalence T | 2018 |
Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Double | 2018 |
Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Double | 2018 |
Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Double | 2018 |
Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Double | 2018 |
Comparison of oral and intravenous lansoprazole for the prevention of bleeding from artificial ulcers after endoscopic submucosal dissection for gastric tumors: a prospective randomized phase II study (KDOG 0802).
Topics: Administration, Oral; Aged; Endoscopic Mucosal Resection; Female; Gastrointestinal Hemorrhage; Hemos | 2018 |
Prospective, randomized comparison of lansoprazole suspension, and intermittent intravenous famotidine on gastric pH and acid production in critically ill neurosurgical patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Critical Illness; Famotidine; Fem | 2010 |
Effect of lansoprazole versus roxatidine on prevention of bleeding and promotion of ulcer healing after endoscopic submucosal dissection for superficial gastric neoplasia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Anti-Ulcer Agents; Cost-Benefit An | 2011 |
Intravenous administration of lansoprazole: a preliminary study of dose ranging and efficacy in upper gastrointestinal bleeding.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agen | 1995 |
[Lansoprazole versus ranitidine in the prevention of early recurrences of digestive hemorrhages from gastroduodenal ulcers. Randomized double-blind multicenter study].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 1994 |
Drug treatments in upper gastrointestinal bleeding: value of endoscopic findings as surrogate end points.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Antifibrinolytic Agents; Blood Transfusi | 2001 |
15 other studies available for lansoprazole and Hematochezia
| Article | Year |
|---|---|
Cost-Effectiveness of Vonoprazan Compared With Proton Pump Inhibitors in Patients Taking Low-Dose Aspirin for Secondary Prevention of Cardiovascular Events in Japan.
Topics: Aged; Aspirin; Cardiovascular Diseases; Cost-Benefit Analysis; Esomeprazole; Gastrointestinal Hemorr | 2023 |
Eosinophilic colitis: an infrequent disease with difficult diagnose.
Topics: Aged, 80 and over; Biopsy; Colitis; Colon; Colonoscopy; Cromolyn Sodium; Drug Therapy, Combination; | 2020 |
Acute upper gastrointestinal bleed in the puerperium following weight reduction surgery.
Topics: Acute Disease; Adult; Bariatric Surgery; Female; Gastrointestinal Hemorrhage; Gastroscopy; Humans; I | 2020 |
A case of idiopathic gastroesophageal submucosal hematoma and its disappearance observed by endoscopy.
Topics: Aged; Anti-Ulcer Agents; Endoscopy, Gastrointestinal; Esophageal Diseases; Esophagogastric Junction; | 2014 |
A rare cause of GI bleeding in a 56-year-old man.
Topics: Anti-Ulcer Agents; Gastrointestinal Hemorrhage; Humans; Lansoprazole; Male; Middle Aged; Mucormycosi | 2017 |
Watermelon stomach.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Follow-Up Studies; Gastric Antral Vascular Ectasia; G | 2008 |
Unique endoscopy findings in collagenous colitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; | 2009 |
Gastroprotection in trauma patients receiving non-steroidal anti-inflammatory drugs.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti- | 2010 |
Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Actinobacteria; Animals; Anti-Inflammatory Agents, Non-Ster | 2011 |
In vitro and in vivo protection against indomethacin-induced small intestinal injury by proton pump inhibitors, acid pump antagonists, or indomethacin-phosphatidylcholine.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis | 2012 |
[Gastric protection and treatment with low-dose aspirin].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; | 2006 |
[Effects of intravenous lansoprazole on acute gastric mucosal lesions and acid secretion].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Animals; Anti-Ulcer Agents; Famotidine; Gast | 1996 |
[Effects of lansoprazole on indomethacin-induced gastric bleeding and mucosal lesions in rats].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Dose-Response Relationship, Dru | 1996 |
Current approaches to reducing gastrointestinal toxicity of low-dose aspirin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; | 2001 |
Lansoprazole-induced thrombocytopenia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Anti-Ulcer Agents; Gastrointestina | 2002 |